Disease

Patients with chronic kidney disease have limited opportunities to engage in shared-decision-making with their physicians, according to a published Danish study.

The autosomal dominant polycystic kidney disease registry may help assess various aspects of disease burden on patients’ health-related quality of life, according to published research.

Patients with rare kidney diseases have greater 5-year rates of kidney failure but higher survival than those with chronic kidney disease stages 3 through 5, according to published data.

Patients with chronic kidney disease may have difficulty accessing equitable treatment even in a country with universal health care, according to published findings.

The FDA has granted a 7-year orphan drug exclusivity period for Tarpeyo, a medication for the treatment of primary immunoglobulin A nephropathy, according to a press release.

Chronic kidney disease stage G3 may be linked with considerable morbidity in a community-based setting, which shows a need for optimized early interventions, according to published data.

The severity of chronic kidney disease-associated pruritus may be linked with higher risks of all-cause mortality, hospitalizations, cardiovascular events and infections, data show.

Patient-reported outcome scores effectively predicted clinical and health-economic outcomes in adults with autosomal dominant polycystic kidney disease, a study found.

Select contaminants within the phthalate class may be linked to more rapid deterioration in kidney function, researchers from New York University found in a recently published study.

A clinical-stage RNA medicines firm has announced the initiation of dosing in a phase 2 clinical trial of its investigational therapy for boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping.